Online inquiry

IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1251MR)

This product GTTS-WQ1251MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets DLL4&VEGFA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_019074.4; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567; 7422
UniProt ID Q9NR61; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1251MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6552MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA D2E7
GTTS-WQ705MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ3966MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ12073MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MOR-00208
GTTS-WQ14173MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-910
GTTS-WQ10536MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ10771MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ6394MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CSL654
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW